Reductil generic makers to face tougher license procedure

Published: 2007-01-30 07:00:00

Updated: 2007-01-30 07:00:00

A number of Korean generic makers to develop the generic version of Reductil capsule (sibutramine hydrochloride) will have to pass through more complicated procedures for the approval of their salt-modified compounds.

In a Q/A session on January 22, the Korea Food and Drug Administration said ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK